Abstract:Prior research has proposed a potential association between lung cancer and inflammatory cytokines, yet the specific causal relationship remains unclear, especially across various lung cancer pathologies. This study utilized bidirectional Mendelian randomization (MR) to explore these causal connections, unveiling novel insights. Our research revealed distinctive inflammatory cytokine profiles for each subtype of lung cancer and identified potential biomarkers that could refine diagnostic and therapeutic approaches. We applied two-sample Mendelian randomization, leveraging genetic variance data from three extensive genome-wide association studies (GWAS) focusing on different lung cancer types (lung adenocarcinoma: 1590 cases and 314,193 controls of healthy individuals of European descent; lung squamous cell carcinoma: 1510 cases and 314,193 controls of European ancestry; small cell lung cancer: 717 cases and 314,193 controls of European ancestry). A separate GWAS summary on inflammatory cytokines from 8,293 healthy participants was also included. The inverse variance weighting method was utilized to examine causal relationships, with robustness confirmed through multiple sensitivity analyses, including MR-Egger, weighted median, and MR-PRESSO. Our analysis revealed that elevated levels of IL_1RA were associated with an increased risk of lung adenocarcinoma (OR: 1.29, 95% CI: 1.02-1.64, p = 0.031), while higher MCP_1_MCAF levels correlated with a decreased risk of lung squamous cell carcinoma (OR: 0.77, 95% CI: 0.61-0.98, p = 0.031). Furthermore, IL_10, IL_13, and TRAIL levels were positively associated with lung squamous cell carcinoma risk (IL_10: OR: 1.27, 95% CI: 1.06-1.53, p = 0.012; IL_13: OR: 1.15, 95% CI: 1.06-1.53, p = 0.036; TRAIL: OR: 1.15, 95% CI: 1.06-1.53, p = 0.043). No association was found between inflammatory cytokine levels and small cell lung cancer development, whereas SDF_1A and B-NGF were linked to an increased risk of this cancer type (SDF_1A: OR: 1.13, 95% CI: 1.05-1.21, p = 0.001; B-NGF: OR: 1.13, 95% CI: 1.01-1.27, p = 0.029). No significant relationship was observed between the 41 circulating inflammatory cytokines and lung adenocarcinoma or squamous cell carcinoma development. Our findings indicate distinct associations between specific inflammatory cytokines and different types of lung cancer. Elevated IL_1RA levels are a risk marker for lung adenocarcinoma, whereas higher MCP_1_MCAF levels appear protective against lung squamous cell carcinoma. Conversely, elevated levels of IL_10, IL_13, and TRAIL are linked with an increased risk of lung squamous cell carcinoma. The relationships of SDF_1A and B-NGF with small-cell lung cancer highlight the complexity of inflammatory markers in cancer development. This study provides a nuanced understanding of the role of inflammatory cytokines in lung cancer, underscoring their potential in refining diagnosis and treatment strategies.

Genetic Variations in Interleukin-8 and Interleukin-10 Are Associated with Pain, Depressed Mood, and Fatigue in Lung Cancer Patients.

Cytokine Gene Polymorphisms and Cancer-Related Symptoms in Lung Cancer Patients

Symptom Clusters of Pain, Depressed Mood, and Fatigue in Lung Cancer: Assessing the Role of Cytokine Genes

Cytokine Genes and Pain Severity in Lung Cancer: Exploring the Influence of TNF-α-308 G/A IL6-174G/C and IL8-251T/A

The Influence of Tumor Necrosis Factor-α −308 G/A and IL-6 −174 G/C on Pain and Analgesia Response in Lung Cancer Patients Receiving Supportive Care

Role of Inflammation Gene Polymorphisms on Pain Severity in Lung Cancer Patients.

Inflammation Genes and Pain Severity in Lung Cancer Patients

Effect of Polymorphism on IL1A to Cancer Susceptibility: Evidence Based on 34,016 Subjects

The Expression Profiling and Clinical Significance of a Chronic Pain-Related Gene IL1R1.

Systematic Evaluation Of Genetic Variants In The Inflammation Pathway And Risk Of Lung Cancer

IL-8 –251A/T Polymorphism is Associated with Decreased Cancer Risk among Population-Based Studies: Evidence from a Meta-Analysis

Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.

Abstract 4662: Genetic Predictors of Clinical Outcomes for Patients with Non-Small Cell Lung Cancer

Genetic Polymorphisms of IL-10, IL-18 and IL12B Are Associated with Risk of Non-Small Cell Lung Cancer in a Chinese Han Population.

Association of Genetic Polymorphism Within Promoter Region of TNF-α, IL-1β and IL-10 with the Susceptibility to Lung Cancer

Integrative genomic expression analysis reveals stable differences between lung cancer and systemic sclerosis

Genetic Variants In Inflammation-Related Genes Are Associated With Radiation-Induced Toxicity Following Treatment For Non-Small Cell Lung Cancer

The Role of Interleukin-31 Polymorphisms in Non-Small Cell Lung Cancer Genetic Susceptibility and Clinical Outcome

Inflammation-related Genetic Variants Predict Toxicity Following Definitive Radiotherapy for Lung Cancer.

Association of IL-1beta gene polymorphism with cachexia from locally advanced gastric cancer

Bidirectional Mendelian Randomization of Causal Relationship between Inflammatory Cytokines and Different Pathological Types of Lung Cancer